Literature DB >> 26766943

Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers.

Ather Muneer1.   

Abstract

Bipolar disorder is a severe and enduring psychiatric condition which in many cases starts during early adulthood and follows a relapsing and remitting course throughout life. In many patients the disease follows a progressive path with brief periods of inter-episode recovery, sub-threshold symptoms, treatment resistance and increasing functional impairment in the biopsychosocial domains. Knowledge about the neurobiology of bipolar disorder is increasing steadily and evidence from several lines of research implicates immuno-inflammatory mechanisms in the brain and periphery in the etiopathogenesis of this illness and its comorbidities. The main findings are an increase in the levels of proinflammatory cytokines during acute episodes with a decrease in neurotrophic support. Related to these factors are glial cell dysfunction, neuro-endocrine abnormalities and neurotransmitter aberrations which together cause plastic changes in the mood regulating areas of the brain and neuroprogression of the bipolar diathesis. Research in the above mentioned areas is providing an opportunity to discover novel biomarkers for the disease and the field is reaching a point where major breakthroughs can be expected in the not too distant future. It is hoped that with new discoveries fresh avenues will be found to better treat an otherwise recalcitrant disease.

Entities:  

Keywords:  Biomarkers; Bipolar disorder; Cytokines; Inflammation; Neurotrophins

Year:  2015        PMID: 26766943      PMCID: PMC4701682          DOI: 10.4306/pi.2016.13.1.18

Source DB:  PubMed          Journal:  Psychiatry Investig        ISSN: 1738-3684            Impact factor:   2.505


  105 in total

Review 1.  Staging bipolar disorder.

Authors:  Eduard Vieta; M Reinares; A R Rosa
Journal:  Neurotox Res       Date:  2010-05-12       Impact factor: 3.911

2.  Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder.

Authors:  Iria Grande; Flávio Kapczinski; Laura Stertz; Gabriela Delevatti Colpo; Mauricio Kunz; Keila Mendes Cereser; Marcia Kauer-Sant'Anna; Benicio Frey; Eduard Vieta; Pedro V S Magalhaes
Journal:  J Psychiatr Res       Date:  2012-08-30       Impact factor: 4.791

3.  Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission.

Authors:  Kuan-Pin Su; Sy-Jye C Leu; Yi-Yuan Yang; Winston W Shen; Yech-Mei Chou; Shang-Ying M Tsai
Journal:  J Affect Disord       Date:  2002-09       Impact factor: 4.839

4.  Increased levels of glutamate in brains from patients with mood disorders.

Authors:  Kenji Hashimoto; Akira Sawa; Masaomi Iyo
Journal:  Biol Psychiatry       Date:  2007-06-15       Impact factor: 13.382

5.  Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

Authors:  Daniel Lindqvist; Shorena Janelidze; Peter Hagell; Sophie Erhardt; Martin Samuelsson; Lennart Minthon; Oskar Hansson; Maria Björkqvist; Lil Träskman-Bendz; Lena Brundin
Journal:  Biol Psychiatry       Date:  2009-03-06       Impact factor: 13.382

6.  S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study.

Authors:  Tomasz Gos; Matthias L Schroeter; Wiebke Lessel; Hans-Gert Bernstein; Henrik Dobrowolny; Kolja Schiltz; Bernhard Bogerts; Johann Steiner
Journal:  J Psychiatr Res       Date:  2013-07-26       Impact factor: 4.791

7.  The role of BDNF as a mediator of neuroplasticity in bipolar disorder.

Authors:  Iria Grande; Gabriel Rodrigo Fries; Mauricio Kunz; Flavio Kapczinski
Journal:  Psychiatry Investig       Date:  2010-12-15       Impact factor: 2.505

Review 8.  Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application.

Authors:  C C Watkins; A Sawa; M G Pomper
Journal:  Transl Psychiatry       Date:  2014-01-21       Impact factor: 6.222

Review 9.  Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness.

Authors:  Michael Berk; Olivia Dean; Hemmo Drexhage; John J McNeil; Steven Moylan; Adrienne O'Neil; Christopher G Davey; Livia Sanna; Michael Maes
Journal:  BMC Med       Date:  2013-03-18       Impact factor: 8.775

Review 10.  Disturbance of the glutamatergic system in mood disorders.

Authors:  Chansoo Jun; Yera Choi; Soo Mee Lim; Sujin Bae; Young Sun Hong; Jieun E Kim; In Kyoon Lyoo
Journal:  Exp Neurobiol       Date:  2014-03-27       Impact factor: 3.261

View more
  39 in total

1.  [Bipolar disorder vulnerability: The vitamin D path].

Authors:  Manel Naifar; Manel Maalej Bouali; Wassim Guidara; Ahmed Slim Ellouze; Khalil Jmal; Sana Omri; Meriam Messedi; Lobna Zouari; Aida Elleuch; Mohamed Maalej; Khansa Chaabouni; Nada Charfi; Mouna Turki; Ben Thabet Jihène; Fatma Ayadi
Journal:  Can J Psychiatry       Date:  2019-08-21       Impact factor: 4.356

2.  Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.

Authors:  Hon-Cheong So; Carlos Kwan-Long Chau; Wan-To Chiu; Kin-Sang Ho; Cho-Pong Lo; Stephanie Ho-Yue Yim; Pak-Chung Sham
Journal:  Nat Neurosci       Date:  2017-08-14       Impact factor: 24.884

3.  Bipolar limbic expression of auto-immune thyroid targets: thyroglobulin and thyroid-stimulating hormone receptor.

Authors:  Meleshni Naicker; Nathlee Abbai; Strinivasen Naidoo
Journal:  Metab Brain Dis       Date:  2019-06-13       Impact factor: 3.584

Review 4.  Allostatic load but not medical burden predicts memory performance in late-life bipolar disorder.

Authors:  Sophie R Vaccarino; Tarek K Rajji; Ariel G Gildengers; Sarah E S Waters; Meryl A Butters; Mahesh Menon; Daniel M Blumberger; Aristotle N Voineskos; Dielle Miranda; Benoit H Mulsant
Journal:  Int J Geriatr Psychiatry       Date:  2017-12-13       Impact factor: 3.485

5.  Human cathelicidin LL-37 - Does it influence the homeostatic imbalance in mental disorders?

Authors:  Elzbieta Kozlowska; Adam Wysokinski; Karol Majewski; Justyna Agier; Aleksandra Margulska; Ewa Brzezinska-Blaszczyk
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

Review 6.  Activation of SIRT-1 Signalling in the Prevention of Bipolar Disorder and Related Neurocomplications: Target Activators and Influences on Neurological Dysfunctions.

Authors:  Bidisha Rajkhowa; Sidharth Mehan; Pranshul Sethi; Aradhana Prajapati
Journal:  Neurotox Res       Date:  2022-02-14       Impact factor: 3.911

7.  Correlations between peripheral levels of inflammatory mediators and frontolimbic structures in bipolar disorder: an exploratory analysis.

Authors:  Satyajit Mohite; Haitham Salem; Thiago Cordeiro; Jonika Tannous; Benson Mwangi; Sudhakar Selvaraj; Jair C Soares; Marsal Sanches; Antonio L Teixeira
Journal:  CNS Spectr       Date:  2021-06-14       Impact factor: 3.790

8.  Metabolomic Characterization of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).

Authors:  Federica Murgia; Antonella Gagliano; Marcello G Tanca; Noga Or-Geva; Aran Hendren; Sara Carucci; Manuela Pintor; Francesca Cera; Fausto Cossu; Stefano Sotgiu; Luigi Atzori; Alessandro Zuddas
Journal:  Front Neurosci       Date:  2021-05-28       Impact factor: 4.677

Review 9.  Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase.

Authors:  Vânia Machado Recart; Luiza Spohr; Mayara Sandrielly Pereira Soares; Karina Pereira Luduvico; Francieli Moro Stefanello; Roselia Maria Spanevello
Journal:  Metab Brain Dis       Date:  2021-07-15       Impact factor: 3.584

Review 10.  Evaluating endophenotypes for bipolar disorder.

Authors:  Riccardo Guglielmo; Kamilla Woznica Miskowiak; Gregor Hasler
Journal:  Int J Bipolar Disord       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.